Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- Santa Barbara, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 13 Sept 2023
- Ended
- 29 May 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard Care
- Culturally-tailored dietary and behavioral intensive lifestyle intervention
- Placebo
- Tirzepatide
- Record updated
- 25 February 2025
- Why it stopped
- The study was discontinued prematurely for administrative reasons
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Self-reported Hispanic and/or Latino heritage
- Body Mass Index (BMI) 30-42 kg/m²
- HbA1c ≤ 6.4%
Who cannot take part
- Unstable weight (≥4% during the last 2 months prior to study enrollment)
- Severe cardiovascular disease within the 6 months prior to study enrollment
- Active substance abuse with alcohol or drugs
- Metal implants that preclude MRI testing
- Use of medications that are known to affect the study outcome measures
- History of chronic or acute pancreatitis
- Medical conditions that cause obesity
- History of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder within the last 2 months
- Uncontrolled hypertension
- Liver disease
- Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- History of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
- Have any other condition not listed in this section (e.g. hypersensitivity or intolerance) that is a contraindication of GLP-1R agonists
- Previous diagnosis of diabetes or fasting glucose ≥ 126 mg/dl or 2 hr oral glucose tolerance test plasma glucose ≥ 200 mg/dl
- Calcitonin level of ≥20 ng/L if eGFR ≥60 mL/min/1.73 m2 or ≥35 ng/L if eGFR <60 mL/min/1.73 m2
- Do not agree to use contraception throughout the study period in male and female participants of reproductive and childbearing age
- CPAP treatment for obstructive sleep apnea
- Severe organ system dysfunction
- Known clinically significant gastric emptying abnormality
- Thyroid-stimulating hormone (TSH) >1.5X the upper limit of normal
- Severe anemia
- Pregnant or breastfeeding
- Persons who are not able to grant voluntary informed consent
- Unable or unwilling to follow the study protocol
Where in United States
- Sansum Diabetes Research InstituteSanta Barbara, United States
About the trial
What the trial wants to find out
The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate, intensive lifestyle intervention (ILI) delivered by community health workers (CHWs) in Latino adults with obesity. Participants will be randomized to 1) standard care (SC, n=25); 2) culturally-tailored dietary and behavioral intensive lifestyle intervention (ILI, n=25) provided by CHWs plus placebo; or 3) ILI plus tirzepatide (ILI-TRZ) for 52 weeks to evaluate the intervention's effect on: i) weight loss; ii) clinical efficacy (change in body fat mass, liver fat, intra-abdominal fat mass and intrahepatic triglyceride content, oral glucose tolerance, glycemic control, insulin sensitivity and b-cell function, plasma lipids, blood pressure, sleep duration, quality and behaviors, physical performance scores); iii) adherence and fidelity to the intervention (adherence to the intervention and barriers to long term adherence, quality-of-life, fidelity of the implementation by CHWs, CHW's and study participants' acceptability and satisfaction with the intervention and eating behaviors. Placebo or tirzepatide will be injected subcutaneously in the abdomen or thigh once a week for 12 months.
The 3 groups in the trial
- Standard CareExisting treatment, for comparison
In this arm, participants will receive the standard care intervention from community health workers.
- Intensive lifestyle intervention plus placeboTreatment being tested
In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.
Treatment: Culturally-tailored dietary and behavioral intensive lifestyle intervention and Placebo
- Intensive lifestyle intervention plus tirzepatideTreatment being tested
In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention
Treatment: Culturally-tailored dietary and behavioral intensive lifestyle intervention and Tirzepatide
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
- Record updated
- 25 February 2025